---
title: "Yingjiexin Medical Raises About $30M Series B for Injection Devices"
description: "Yingjiexin Medical disclosed approximately $30 million Series B financing on November 2, 2026, to scale injection pens and delivery-device manufacturing."
date: 2026-11-02T00:00:00.000Z
source: https://venturecapitaltracker.com/yingjiexin-medical-200m-rmb-series-b-2026
---

# Yingjiexin Medical Raises About $30M Series B for Injection Devices

> Yingjiexin Medical disclosed approximately $30 million Series B financing on November 2, 2026, to scale injection pens and delivery-device manufacturing.

## What happened

Yingjiexin Medical disclosed approximately $30 million Series B financing on November 2, 2026, to scale injection pens and delivery-device manufacturing.

## The company and market

The Shanghai medtech company's market includes injection-device platforms used to administer GLP-1, insulin and other biologic medicines.

## Financing, ownership and investors

A CICC Capital-managed fund led the financing, with other reported institutional and industrial participants. The funding is allocated toward capacity, product development and international market access.

## Product, technology and operating milestones

Self-administered biologics create a supply-chain opportunity for device manufacturers, but drug demand does not automatically translate into approved orders for any specific component supplier.

## Why this matters for venture capital

Competitive differentiation depends on dosage reliability, manufacturing yield, regulatory clearance, contract duration and customer concentration.

## What remains unverified

VCT has no public revenue, unit shipment or device-specific regulatory approval figures from the cited announcement; these should not be inferred.

## Key facts

| Field | Reported detail |
|---|---|
| Company | Yingjiexin Medical |
| Announcement date | 2026-11-02 |
| Classification | Startup venture financing |
| Evidence | Primary or dated specialist reporting, linked in VCT's source section |

## Related VCT coverage

Review the linked startup profile and canonical investment event for funding history, investor relationships and corrected event dates. The company-reported claims above are distinguished from independently verified transaction facts.

## Currency conversion

The USD equivalent uses the European Central Bank reference exchange rates from October 30, 2026, the most recent published fixing before the November 2 announcement. Amounts are rounded, and company-reported qualifiers such as 'about' or 'more than' are preserved; these are not separately disclosed USD-denominated transactions.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 2, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.